Taiwan Liposome Company

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Taiwan Liposome Company sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials none currently recruiting 7 completed early-phase tilt upper quartile by trial count

Taiwan Liposome Company: 7 sponsored US clinical trials, none currently recruiting.

Taiwan Liposome Company sponsors 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 1 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Osteoarthritis of the Knee, with 1 trials.

Upper-quartile sponsor footprint

Taiwan Liposome Company sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

7 total, page 1 of 1

COMPLETED Phase 3

Extended and Controlled Release Liposomal Formulated Dexamethasone for Chronic Knee OA Pain

NCT04123561
COMPLETED Phase 2

A Study to Evaluate Safety, PK, Efficacy of TLC590 for Postsurgical Pain Management Following Bunionectomy

NCT03838133
COMPLETED Phase 2

A Phase 2, Open Label, Pharmacokinetic (PK) Study of TLC599 in Subjects With Osteoarthritis of the Knee

NCT03754049
COMPLETED Phase 1

Phase I/II Dose-escalation Study to Evaluate Safety, PK and Efficacy of TLC590 for Postsurgical Pain Management

NCT03591146
COMPLETED Phase 1

Dose-escalation Study of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy

NCT02925000
COMPLETED Phase 2

TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

NCT03093701
COMPLETED Phase 1

Phase I Study of Intravenous Lipotecan® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors

NCT00747474

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 3
Phase 3 1

Therapeutic Areas

Osteoarthritis of the Knee 1

How the Taiwan Liposome Company early-phase archive is shaped

7 indexed studies, none listed as recruiting (0% open); 7 completed (100%).

Phase mix: 1 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Osteoarthritis of the Knee (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Taiwan Liposome Company: archived-pipeline peers nationwide

Peers matched on 7 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Taiwan Liposome Company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Taiwan Liposome Company3M4Life Research89bioAbbott Diagnostics Division10xBio22nd Century Group23andMe3-C Institute for Social Development
Taiwan Liposome Company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Taiwan Liposome Company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Taiwan Liposome Company page

7 registered trials is a research-attention snapshot, not an endorsement of Taiwan Liposome Company or any single study.

  • None of Taiwan Liposome Company's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Osteoarthritis of the Knee is the condition Taiwan Liposome Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Osteoarthritis of the Knee trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Taiwan Liposome Company pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.